Skip to main content
Premium Trial:

Request an Annual Quote

Ochsner Health Integrating ActX Genomic Decision Support to Pilot Cancer PGx Project

NEW YORK – New Orleans-based Ochsner Health on Wednesday said it is piloting a pharmacogenomics project, in which it will integrate ActX Genomic Decision Support within its Epic electronic health records to alert doctors to how cancer patients are likely to respond to various drugs based on their genomic profile.

The ActX platform will allow physicians to check drug-gene interactions in real time in the EHR workflow against the therapies cancer patients are prescribed, provide a genomic profile in each patient's chart, and enable assessment of actionable hereditary risks. The decision support system will alert doctors if, based on patients' genomic profiles, they are likely to have a limited response to a drug or experience adverse reactions, or if they need a different drug dose.

"The ability to predict ahead of time which drugs will be effective for a unique patient across many different clinical scenarios and to identify in real time which medications may cause patients serious issues, will save lives and improve the quality of our care while also being more cost effective," Marc Matrana, director of Ochsner Precision Cancer Therapies Program, said in a statement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.